Success Story: NIW Granted to Egyptian Assistant Professor in Only 23 Days via Premium Processing Service with Our Expert Team

 

Client’s Testimonial:

“Thank you for your help and efforts. It has been a pleasure working with you.”


On April 16th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for an Assistant Professor in the Field of Diagnostic and Molecular Pathology (Approval Notice).


General Field: Diagnostic and Molecular Pathology

Position at the Time of Case Filing: Assistant Professor

Country of Origin: Egypt

State of Residence at the Time of Filing: West Virginia

Approval Notice Date: April 16th, 2025

Processing Time: 23 days (Premium Processing Requested)


Case Summary:

We are proud to share the successful I-140 NIW approval of a highly accomplished MBBCh holder from Egypt whose work is transforming how healthcare systems understand and address genetic, molecular, and health disparity-related factors in cancer and infectious diseases. His research integrates advanced pathology diagnostics to uncover biomarkers, molecular pathways, and population-specific risk factors that directly support precision medicine and equitable healthcare outcomes.

Currently working as an assistant professor in the United States, the client’s proposed endeavor focuses on identifying molecular mechanisms underlying colorectal cancer and COVID-19, with a particular emphasis on health disparities affecting African American populations. His research informs therapeutic development, personalized diagnostics, and strategies to close racial gaps in health outcomes, an area of clear national importance.

To support his petition under the National Interest Waiver (NIW) category, we highlighted:

● A publication record of 7 peer-reviewed journal articles and 20 conference abstracts, including several first-authored works in prominent journals;

● 127 total citations, with 2 articles ranked in the top 10% most cited in clinical medicine for their publication years;

● Peer-reviewed funding support, significant adoption of his research by other investigators, and influence on public health and oncology research across disciplines.

His studies have been cited in meta-analyses and research on colorectal cancer survival inequalities, COVID-19-related inflammation, and molecular pathways of disease progression. These citations affirm the originality and applied value of his work in both clinical and academic contexts.

The petition was approved in just 23 days via direct premium processing, with strong documentation of his national impact and scholarly significance.

We congratulate him on this important achievement and look forward to his continued leadership in molecular diagnostics and equitable healthcare innovation.